Showing posts with label Transfection Reagents and Equipment Market. Show all posts
Showing posts with label Transfection Reagents and Equipment Market. Show all posts

Tuesday, July 27, 2021

Transfection Reagents and Equipment Market - Global Key Players & Different Growth Strategies Adopted by Them

 The key players in this market are continuously striving to gain larger shares and expand their existing product portfolios by agreements, collaborations, and partnerships. The overall market was dominated by Thermo Fisher Scientific Inc. (U.S.), Promega Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and QIAGEN N.V. (Netherlands). Other players include Polyplus-transfection SA (France), Bio-Rad Laboratories Inc. (U.S.), Lonza Group (Switzerland), Sigma-Aldrich Corporation (U.S.), Mirus Bio LLC (U.S.), and MaxCyte, Inc. (U.S.).


Thermo Fisher Scientific Inc. (U.S.) is leading player in the transfection reagents and equipment market with a market share of ~61.5% in 2015. The company primarily focuses on growth strategies such as acquisitions to add innovative technologies and products to its portfolio, which in turn helps the company to strengthen its presence in the respective markets. Thermo Fisher acquired Affymetrix, Inc. (U.S.) in 2016, Advanced Scientifics, Inc. (U.S.) in 2015, and Life Technologies Corporation (U.S.) in 2014. This helped the company to expand its customer base and significantly boost its market share. The company’s major share in the transfection reagents and equipment market can be attributed to its broad product portfolio, years of experience, and extensive distribution channel.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=139141146

The R&D expenditure of the company for 2015 was USD 690 million, which enabled it to expand its product portfolio in the transfection reagents and equipment market, and to further enhance its customer base. In November 2014, Thermo Fisher Scientific introduced its Lipofectamine MessengerMAX, a high-efficiency transfection reagent for mRNA delivery in neurons and primary cell types. It is five times more efficient as compared to DNA reagents and helps researchers in easy transfection of biologically relevant cell models without electroporation or viruses. The company‘s distribution network comprises a broad sales force and global network of resellers and distributors. Thermo Fisher has approximately 17,500 sales and service personnel, including over 3,000 trained technical specialists who address the diversified demands of technical end users.

Promega Corporation (U.S.) is another dominant player in the transfection reagents and equipment market. The company accounted for approximately ~17.4% of the market revenue generation. The firm offers more than 3000 products for life science research, particularly in genomics, protein analysis and expression, cellular analysis, drug discovery, and genetic identity. It offers various transfection reagents under its reporter assays and transfection category of products. Promega has branches in 16 countries with more than 50 global distributors. The company possesses a strong intellectual property portfolio, which helps it to maintain its position in the life science market. Promega owns more than hundred patents in the field of nucleic acid purification, human identification, bioluminescence, coupled in vitro transcription and translation, and cell biology. The company focuses on the strategy of new product development and expansion to strengthen its position in the market.

Players operating in the transfection reagents and equipment market adopted strategies such as agreements, collaborations, and partnerships to strengthen their global presence. The key players that have adopted these strategies include MaxCyte, Inc. (U.S.), Polyplus-transfection SA (France), QIAGEN N.V. (Netherlands), Lonza Group Ltd. (Switzerland), F. Hoffmann-La Roche ltd (Switzerland), and Thermo Fisher Scientific Inc. (U.S.).

Expected Revenue Growth:

The global transfection reagent market includes forecast from 2016 to 2021. This market is expected to reach USD 1.02 Billion by 2021 from USD 715.4 Million in 2016, at a CAGR of 7.5% during the forecast period.

Growth Boosting Factors:

This growth can be attributed to factors such as advancements in transfection technology, global alliances among leading research institutes to trigger drug discovery, increase in R&D spending and research activities by pharmaceutical and biotechnology companies, increase in demand for synthetic genes, and rising incidence of cancer. Moreover, development of large scale transfections, rising demand of protein therapeutics, and emerging markets across India and China are likely to create opportunities for players operating in the market.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=139141146

Geographical Growth Scenario:

On the basis of region, the global transfection reagents and equipment market is divided into North America, Europe, Asia-Pacific, and Rest of the World (RoW). In 2016, North America is poised to account for the largest share of the market, followed by Europe and Asia-Pacific. However, the Asia-Pacific market is slated to grow at the highest CAGR during the forecast period and serve as a major revenue pocket for companies offering transfection reagents and equipment.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Wednesday, July 8, 2020

Transfection Reagents and Equipment Market - Global Leaders and Growth Strategies Adopted by Them

The global growth of the transfection reagent market can be attributed to factors such as advancements in transfection technology, global alliances among leading research institutes to trigger drug discovery, increase in R&D spending and research activities by pharmaceutical and biotechnology companies, increase in demand for synthetic genes, and rising incidence of cancer.

Moreover, development of large scale transfections, rising demand of protein therapeutics, and emerging markets across India and China are likely to create opportunities for players operating in the market.

The global transfection reagent market includes forecast from 2016 to 2021. This market is expected to reach USD 1.02 Billion by 2021 from USD 715.4 Million in 2016, at a CAGR of 7.5% during the forecast period.

The global transfection equipment market is segmented on the basis of product, method, application, end user, and region. Based on product, the market is segmented into reagents and instruments. In 2016, the reagents segment is estimated to account for the largest share of the market. However, the instruments segment is expected to grow at the highest CAGR during the forecast period.

Download PDF Brochure@

Major Leaders:

The overall market was dominated by Thermo Fisher Scientific Inc. (U.S.), Promega Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and QIAGEN N.V. (Netherlands). Other players include Polyplus-transfection SA (France), Bio-Rad Laboratories Inc. (U.S.), Lonza Group (Switzerland), Sigma-Aldrich Corporation (U.S.), Mirus Bio LLC (U.S.), and MaxCyte, Inc. (U.S.).

Growth Strategies Adopted by Them:

The key players in this market are continuously striving to gain larger shares and expand their existing product portfolios by agreements, collaborations, and partnerships.

Thermo Fisher Scientific Inc. (U.S.) is leading player in the transfection reagents and equipment market with a market share of ~61.5% in 2015. The company primarily focuses on growth strategies such as acquisitions to add innovative technologies and products to its portfolio, which in turn helps the company to strengthen its presence in the respective markets.

Thermo Fisher acquired Affymetrix, Inc. (U.S.) in 2016, Advanced Scientifics, Inc. (U.S.) in 2015, and Life Technologies Corporation (U.S.) in 2014. This helped the company to expand its customer base and significantly boost its market share. The company’s major share in the transfection reagents and equipment market can be attributed to its broad product portfolio, years of experience, and extensive distribution channel.

Target Audience:

# Biopharmaceutical companies
# Biotechnology companies
# Transfection equipment, reagent, and kit manufacturing companies
# Suppliers and distributors of transfection reagents
# Research institutes
# Academic centers
# Venture capitalists

Promega Corporation (U.S.) is another dominant player in the transfection reagents and equipment market. The company accounted for approximately ~17.4% of the market revenue generation. The firm offers more than 3000 products for life science research, particularly in genomics, protein analysis and expression, cellular analysis, drug discovery, and genetic identity. It offers various transfection reagents under its reporter assays and transfection category of products.

Promega has branches in 16 countries with more than 50 global distributors. The company possesses a strong intellectual property portfolio, which helps it to maintain its position in the life science market. Promega owns more than hundred patents in the field of nucleic acid purification, human identification, bioluminescence, coupled in vitro transcription and translation, and cell biology. The company focuses on the strategy of new product development and expansion to strengthen its position in the market.

Request Sample Pages@

Players operating in the transfection reagents and equipment market adopted strategies such as agreements, collaborations, and partnerships to strengthen their global presence.

The key players that have adopted these strategies include MaxCyte, Inc. (U.S.), Polyplus-transfection SA (France), QIAGEN N.V. (Netherlands), Lonza Group Ltd. (Switzerland), F. Hoffmann-La Roche ltd (Switzerland), and Thermo Fisher Scientific Inc. (U.S.)

Wednesday, September 25, 2019

Transfection Reagents and Equipment Market - Emerging Industry Dynamics | Global Future Forecasts

This report aims to provide insights into the global Transfection Reagents and Equipment Market. Details on regional markets for these segments are also presented in this report. In addition, leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market.

Target Audience for this Report:

# Biopharmaceutical companies
# Biotechnology companies
# Transfection equipment, reagent, and kit manufacturing companies
# Suppliers and distributors of transfection reagents
# Research institutes
# Academic centers
# Venture capitalists

Looking Out for More Details | Don’t Hesitate to Download the PDF Brochure@

Factors Influencing Global Growth:-

This growth can be attributed to factors such as advancements in transfection technology, global alliances among leading research institutes to trigger drug discovery, increase in R&D spending and research activities by pharmaceutical and biotechnology companies, increase in demand for synthetic genes, and rising incidence of cancer.

Moreover, development of large scale transfections, rising demand of protein therapeutics, and emerging markets across India and China are likely to create opportunities for players operating in the market.

Restraints:
# Selective Effectiveness of Transfection Reagents
# Home Brew Reagents Restrict Sale of Commercial Kits
# High Cost of Transfection Reagents

Opportunities:
# Large-Scale Transfections
# High-Growth Opportunities in Asian Market

Challenges:
# Transfection in Hard-To-Transfect Cells
# Cytotoxicity in Transfection - A Major Concern

Monetary Growth Expectations, Globally:

This report studies the global transfection reagents and equipment market from 2016 to 2021. This market is expected to reach USD 1.02 Billion by 2021 from USD 715.4 Million in 2016, at a CAGR of 7.5% during the forecast period.

Geographical Growth Scenario:

On the basis of region, the global transfection reagents and equipment market is divided into North America, Europe, Asia-Pacific, and Rest of the World (RoW).

In 2016, North America is poised to account for the largest share of the market, followed by Europe and Asia-Pacific. However, the Asia-Pacific market is slated to grow at the highest CAGR during the forecast period and serve as a major revenue pocket for companies offering transfection reagents and equipment.

Read More:

Leading Market Players:

# Thermo Fisher Scientific Inc. (U.S.)
# Promega Corporation (U.S.)
# Hoffmann-La Roche Ltd. (Switzerland)
# QIAGEN N.V. (Netherlands) and many more…

Players operating in the transfection reagents and equipment market adopted strategies such as agreements, collaborations, and partnerships to strengthen their global presence.

Wednesday, September 26, 2018

Transfection Reagents and Equipment - Proposed Technological Innovations & Global Future Forecasts

The global transfection reagents market is expected to reach USD 1.02 Billion by 2021 from USD 715.4 Million in 2016, at a CAGR of 7.5% during the forecast period. 

The key factors driving the growth of this market are technology advancements in transfections, global alliances among leading research institutes to trigger drug discovery, increase in R&D spending and research activities by pharmaceutical and biotechnology companies, increase in demand for synthetic genes, and rising incidence of cancer. On the other hand, factors such as selective effectiveness of transfection reagents, home brew reagents by researchers, and high cost of transfection reagents are expected to limit the growth of the market.

Download the PDF Brochure For More Details: http://bit.ly/2Q6Hh4e

The global transfection reagents market is segmented on the basis of product, method, application, end user, and region. On the basis of product, the market is segmented into reagents and instruments. In 2016, the reagents segment is estimated to account for the largest share of the market. However, the instruments segment is expected to grow at the highest CAGR during the forecast period.

On the basis of method, the market is segmented into biochemical, physical, and viral. In 2016, the biochemical method segment is expected to command the largest share of the market. However, the viral method segment is projected to grow at the highest CAGR during the forecast period. The biochemical method segment is further divided into calcium phosphate, lipofection, DEAE-dextran, and dendrimer. In 2016, the lipofection segment is likely to account for the largest share of the market. Similarly, the physical method segment is classified into electroporation, nucleofection, and others (genegun, sonoporation, magnetofection, and optoinjection). In 2016, the electroporation segment is projected to account for the highest share of the market.

On the basis of end user, the market is segmented into academic & research institutes and pharmaceutical & biotechnologies companies. In 2016, the academic & research institutes is expected to account for the largest share of the market. However, the pharmaceutical & biotechnologies companies segment is projected to grow at the highest CAGR during the forecast period.

On the basis of application, the market is segmented into biomedical research, protein production, and therapeutic delivery. In 2016, the biomedical research segment is poised to account for the largest share of the market. However, the therapeutic delivery segment is expected to grow at the highest CAGR during the forecast period.

On the basis of region, the global transfection reagents market is segmented into North America, Europe, Asia-Pacific, and RoW. In 2016, North America is poised to account for the largest share of the market, followed by Europe and Asia-Pacific. However, the Asia-Pacific market is slated to grow at the highest CAGR during the forecast period and serve as a major revenue pocket for companies offering transfection reagents and equipment.

Read the Detailed Article@ 

Some of the major players in the global transfection reagents market include Thermo Fisher Scientific, Inc. (U.S.), Promega Corporation (U.S.), Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Polyplus-transfection SA (France), Bio-Rad Laboratories (U.S.), Lonza Group (Switzerland), Sigma-Aldrich Corporation (U.S.), Mirus Bio LLC (U.S.), and MaxCyte Inc.(U.S.).

Target Audience
  • Biopharmaceutical companies
  • Biotechnology companies
  • Transfection equipment, reagent, and kit manufacturing companies
  • Suppliers and distributors of transfection reagents
  • Research institutes
  • Academic centers
  • Venture capitalists